Should I Buy EMBC? EMBC 2026 Analysis

Should You Buy Embecta Corp (EMBC) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

10.870

1 Day change

3.77%

52 Week Range

17.870

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient investor: trend is still bearish (SMA_200 > SMA_20 > SMA_5) and there is a major binary catalyst (earnings pre-market 2026-02-05) with elevated implied volatility.
Today’s +4.31% bounce looks more like a short-term pop within a broader downtrend; upside is capped near 12.08–12.67 unless the stock can reclaim key moving averages.
Sentiment from options positioning leans bullish (low put/call OI), but actual option trading activity is extremely thin, reducing confidence in that signal.

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend/structure: Bearish moving-average stack (SMA_200 > SMA_20 > SMA_5) implies the primary trend is still down despite today’s bounce.
MACD: Histogram at -0.0458 (below zero) and negatively contracting → downside momentum is easing, but not yet a confirmed bullish reversal.
RSI(6): 58.584 (neutral-to-slightly-positive) → supports the idea of a bounce, not a clear breakout.
Key levels: Pivot 11.107 is the near-term line to hold; support at 10.138 then 9.54. Resistance at 12.075 (R1) then 12.673 (R2). A clean move above 12.08 would be the first meaningful technical improvement.
Pattern-based odds: Similar-pattern study suggests modest expected drift (next day +0.28%, next week -0.13%, next month +2.29%), i.e., no strong edge right now.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning: Open-interest put/call ratio at 0.47 indicates more call OI than put OI (bullish skew).
Activity/quality of signal: Today’s option volume is essentially nonexistent (total volume 1; put volume 0), so the volume-based sentiment read is not very reliable.
Volatility: 30D IV ~74.1 vs historical vol ~42.53; IV percentile ~71.7 → market is pricing an elevated move (consistent with imminent earnings). This typically makes options expensive and raises the bar for a favorable risk/reward if initiating new positions right before the event.
Open interest: Total OI ~4072 (calls 2773 vs puts 1299) supports the bullish skew, but without volume confirmation it’s more “positioning” than “fresh conviction.”

Technical Summary

Sell

Buy

Positive Catalysts

or upbeat guidance could trigger a sharp upside re-rating given the elevated IV.
keeps the door open for a push toward 12.08 resistance.

Neutral/Negative Catalysts

- Event risk: Earnings pre-market tomorrow with elevated IV implies a large potential gap move; for an impatient buyer, entry timing is unfavorable.
- Core growth concern: Revenue declined -7.72% YoY in 2025/Q4, which can pressure the stock if the market focuses on top-line deterioration.
- Trend remains bearish by moving averages; failure to clear 12.08–12.67 keeps rallies vulnerable to fade.
- No supportive news flow in the past week to offset the earnings binary risk.

Financial Performance

Latest quarter: 2025/Q4.
Revenue: 264.0M, -7.72% YoY (top-line contraction remains a key issue).
Net income: 26.4M, +80.82% YoY (strong improvement, likely cost/mix driven).
EPS: 0.44, +76.00% YoY (profitability trend improved versus last year).
Gross margin: 59.09%, down -1.30% YoY (some margin pressure despite net income growth).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst rating/price target change data: Not provided in the dataset, so recent upgrades/downgrades and target revisions cannot be verified here.
Wall Street-style pros (based on available fundamentals): materially improved EPS/net income trend could attract value/turnaround interest.
Wall Street-style cons: declining revenue and still-bearish technical trend can keep skeptics focused on demand/headwind risk.
Influential trading checks: Hedge funds neutral; insiders neutral; no recent Congress trading data available; no notable politician/influencer buying/selling information provided.

Analyst Rating

Wall Street analysts forecast EMBC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EMBC is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 10.470

Low

Averages

High

Current: 10.470

Low

Averages

High

BofA

Underperform

downgrade

$18 -> $11

AI Analysis

2025-08-08

Reason

BofA

Price Target

$18 -> $11

AI Analysis

2025-08-08

downgrade

Underperform

Reason

BofA lowered the firm's price target on Embecta to $11 from $18 and keeps an Underperform rating on the shares. The firm notes the company's Q3 revenue of $296M was $17M better than Street's $278M driven by ordering timing benefit from distribution stocking ahead of July 4th holiday, incremental stocking related to brand transition and $7M favorable pricing driven by year-to-date rebate reserve adjustments in the U.S. In Q4, Embecta expects revenues to step down to $265M as order timing benefit reverses, FX to be a $3M incremental h/w and China revenues decline quarter-over-quarter. BofA remains bearish on the stock as it does not see much revenue growth.

Mizuho

Neutral

downgrade

$13 -> $12

2025-07-16

Reason

Mizuho

Price Target

$13 -> $12

2025-07-16

downgrade

Neutral

Reason

Mizuho lowered the firm's price target on Embecta to $12 from $13 and keeps a Neutral rating on the shares. The firm adjusted price targets in medical devices and diagnostics ahead of the Q2 reports.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EMBC

Unlock Now

EMBC Should I Buy

EMBC Should I Buy

Should You Buy Embecta Corp (EMBC) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch